Cullinan Therapeutics (NASDAQ:CGEM) vs. Mosaic ImmunoEngineering (OTCMKTS:CPMV) Financial Analysis

Cullinan Therapeutics (NASDAQ:CGEM) and Mosaic ImmunoEngineering (OTCMKTS:CPMV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Institutional & Insider Ownership

86.3% of Cullinan Therapeutics shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by company insiders. Comparatively, 81.0% of Mosaic ImmunoEngineering shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Cullinan Therapeutics and Mosaic ImmunoEngineering”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88 million	($3.36)	-5.48
Mosaic ImmunoEngineering	N/A	N/A	-$690,000.00	($0.09)	-7.49

Mosaic ImmunoEngineering is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for Cullinan Therapeutics and Mosaic ImmunoEngineering, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1	1	6	0	2.63
Mosaic ImmunoEngineering	0	0	0	0	0.00

Cullinan Therapeutics presently has a consensus target price of $32.00, indicating a potential upside of 73.72%. Given Cullinan Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Cullinan Therapeutics is more favorable than Mosaic ImmunoEngineering.

Profitability

This table compares Cullinan Therapeutics and Mosaic ImmunoEngineering’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Mosaic ImmunoEngineering	N/A	N/A	-1,908.81%

Risk & Volatility

Cullinan Therapeutics has a beta of -0.01, suggesting that its share price is 101% less volatile than the S&P 500. Comparatively, Mosaic ImmunoEngineering has a beta of -0.84, suggesting that its share price is 184% less volatile than the S&P 500.

Summary

Cullinan Therapeutics beats Mosaic ImmunoEngineering on 7 of the 11 factors compared between the two stocks.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.